Incremental Value of 111-In Pentetreotide SPECT/CT Fusion Imaging of Neuroendocrine Tumors

Academic Radiology

Volumn 17, Issue 3, 2010, Pages 291-297

  Wong, Ka Kit ^a   Cahill, John M ^a   Frey, Kirk A ^a   Avram, Anca M ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTETREOTIDE IN 111; SOMATOSTATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER LOCALIZATION; CARCINOID; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MACROPHAGE ACTIVATION; MALE; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; NEUROIMAGING; PANCREAS ISLET CELL TUMOR; PARAGANGLIOMA; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID MEDULLARY CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN; SUBTRACTION TECHNIQUE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 75749139629     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2009.08.015     Document Type: Article

References (15)

1. Krenning E.P., Kwekkeboom D.J., Bakker W.H., et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20 (1993) 716-731
2. Rufini V., Calcagni M.L., and Baum R.P. Imaging of neuroendocrine tumors. Semin Nucl Med 36 (2006) 228-247
3. de Herder W.W., Kwekkeboom D.J., Valkema R., et al. Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest 28 (2005) 132-136
4. Buck A.K., Nekolla S., Ziegler S., et al. SPECT/CT. J Nucl Med 49 (2008) 1305-1319
5. Bybel B., Brunken R.C., DiFilippo F.P., et al. SPECT/CT imaging: clinical utility of an emerging technology. Radiographics 28 (2008) 1097-1113
6. Ruf J., Steffen I., Mehl S., et al. Influence of attenuation correction by integrated low-dose CT on somatostatin receptor SPECT. Nucl Med Commun 28 (2007) 782-788
7. Even-Sapir E., Keidar Z., Sachs J., et al. The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms. J Nucl Med 42 (2001) 998-1004
8. Moreira A.P., Duarte L.H., Vieira F., et al. Value of SPET/CT image fusion in the assessment of neuroendocrine tumours with 111In-pentetreotide scintigraphy. Rev Esp Med Nucl 24 (2005) 14-18
9. Perri M., Erba P., Volterrani D., et al. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging 52 (2008) 323-333
10. Krausz Y., Keidar Z., Kogan I., et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxford) 59 (2003) 565-573
11. Pfannenberg A.C., Eschmann S.M., Horger M., et al. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging 30 (2003) 835-843
12. Gabriel M., Hausler F., Bale R., et al. Image fusion analysis of (99 m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med Mol Imaging 32 (2005) 1440-1451
13. Amthauer H., Denecke T., Rohlfing T., et al. Value of image fusion using single photon emission computed tomography with integrated low dose computed tomography in comparison with a retrospective voxel-based method in neuroendocrine tumours. Eur Radiol 15 (2005) 1456-1462
14. Hillel P.G., van Beek E.J.R., Taylor C., et al. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours. Clin Radiol 61 (2006) 579-587
15. Ingui C.J., Shah N.P., and Oates M.E. Endocrine neoplasm scintigraphy: added value of fusing SPECT/CT images compared with traditional side-by-side analysis. Clin Nucl Med 31 (2006) 665-672